Filling the gap in CNS drug development: evaluation of the role of drug repurposing. - Wikidata - awgldk - TriplyDB

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

http://www.wikidata.org/entity/Q33604666

about

Immune-based strategies for mood disorders: facts and challenges.Drug repurposing may generate novel approaches to treating depression.The promise and challenges of drug repurposing in psychiatry.Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory.

P2860

Q47694934-9CFBF58E-C5CB-48A4-9AD3-3B16DF1ABD00 Q47765380-7BED9F35-0429-4662-9B80-AE6D825883E5 Q49598397-1EFFDD4D-D608-4EFC-837B-06D3AABD9ED0 Q49886772-C42653CC-EA3E-479A-BF93-9F5BD39E37EA

P2860

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

http://www.wikidata.org/entity/Q33604666

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@ast

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@en

type

label

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@ast

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@en

prefLabel

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@ast

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@en

P1433

Q33604666-9950C392-8438-4C6F-9438-FE8BE63E0189

P1476

Q33604666-72FF2F36-635E-4C88-94DD-7E239708BCCA

P2093

Q33604666-43770808-044F-4E43-A4B7-A8750C5EADB3

Q33604666-45235386-656C-452F-82CE-55F5E5A2813D

Q33604666-591998BC-DB95-41E5-9059-469BA6CE7151

Q33604666-59C9241E-F56F-433E-892A-EF9EAC61397B

Q33604666-6DB8245D-9630-4F4B-8627-058335BDBC3C

Q33604666-6FF7AEDA-F1A8-4261-8BC3-D0467DA373F9

Q33604666-73038FA8-9085-43F6-8D6A-791FB6AC0404

P2860

Q33604666-033A54F7-EA80-4F17-AA97-FE3A0E7C58D5

Q33604666-15E7650A-0B0C-4E3D-B8F6-B0FF88B6C1FB

Q33604666-166E8FBC-6306-4451-A928-BD29C5663A72

Q33604666-213008CD-22FE-4C5A-A337-93F4DEE2CD21

Q33604666-21D55D76-F201-4E8A-8402-8C0C5443A8D8

Q33604666-40A61B14-37F4-4B18-ACCF-EDB34FC74C82

Q33604666-440927E6-A06E-48F3-85F7-6F8E90EE36A7

Q33604666-A8195910-C089-48A0-9C6F-E37CFC96A097

Q33604666-B2A87F23-562C-4C83-B04C-5834004F825E

Q33604666-C3B61155-36AB-4228-AABD-6CC401481638

P304

Q33604666-310DC00C-EA2B-423D-A779-4C4E3E2518CB

P31

Q33604666-FCF4F8E6-EAB1-48ED-BB5F-2A24FCFA091D

P356

Q33604666-F347FB2A-8F91-4580-B15D-CBB143EF0BB1

P433

Q33604666-6CC669E8-2F5A-4018-84B5-02C5CE25CA4B

P478

Q33604666-328908D7-EE4E-4A22-8DEF-E32C9C7D9250

P577

Q33604666-AF05E7C7-6216-4CE7-A828-B888D477745A

P698

Q33604666-AB76376C-C55F-4F3F-95CF-B1D63FB9CE0D

P932

Q33604666-5C7A2592-3CF4-40B5-8F45-232940F518B9

P356

20016689.2017.1299833

P1433

Journal of market access & health policy

P1476

Filling the gap in CNS drug development: evaluation of the role of drug repurposing.

@en

P2093

A Caban

http://www.w3.org/2001/XMLSchema#string

A Kapuśniak

http://www.w3.org/2001/XMLSchema#string

A Kornfeld

http://www.w3.org/2001/XMLSchema#string

C Rémuzat

http://www.w3.org/2001/XMLSchema#string

K Kopacz

http://www.w3.org/2001/XMLSchema#string

K Pisarczyk

http://www.w3.org/2001/XMLSchema#string

M Toumi

http://www.w3.org/2001/XMLSchema#string

P2860

International comparison of comparative effectiveness research in five jurisdictions: insights for the US

Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Can the pharmaceutical industry reduce attrition rates?

Update on deep brain stimulation in Parkinson's disease.

Drug development for CNS disorders: strategies for balancing risk and reducing attrition.

Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications.

Drug repositioning: re-investigating existing drugs for new therapeutic indications.

Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research.

P304

1299833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/20016689.2017.1299833

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28473889

http://www.w3.org/2001/XMLSchema#string

P932

5405562

http://www.w3.org/2001/XMLSchema#string